Innovation in development of dermatologic drugs approved by the FDA
About The Study: Compared with prior decades, the number of new dermatologic drug approvals by the Food and Drug Administration (FDA) increased between 2012 and 2022. Nearly half of these drugs were considered first in class or first in indication, and several were deemed clinically useful or to have high added therapeutic benefit by health technology assessment organizations in Germany, Canada, or France.
Authors: Ravi Gupta, M.D., M.S.H.P., of the Johns Hopkins University School of Medicine ...














